AFFILIATIONS
1 Dep of Haematology, Monash Health, Melbourne, Victoria, Australia, Dep of Haematology, The Alfred, Melbourne, Victoria, Australia, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia
2 Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, Princess Alexandra Hospital, Brisbane, Queensland, Australia
3 Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, The University of Sydney, Sydney, New South Wales, Australia
4 Royal Adelaide Hospital, Adelaide, South Australia, Australia
5 Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, The University of Western Australia, Perth, Western Australia, Australia
6 St Vincent's Hospital, Melbourne, Victoria, Australia
7 NSW Health Pathology, Sydney, New South Wales, Australia, St George Hospital, Kogarah, New South Wales, Australia, The Sutherland Hospital, Caringbah, New South Wales, Australia, University of New South Wales, Sydney, New South Wales, Australia
8 James Cook University, Townsville, Queensland, Australia, The Townsville Hospital, Townsville, Queensland, Australia
9 Dep of Haematology, Monash Health, Melbourne, Victoria, Australia, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
10 Gosford Hospital, Gosford, New South Wales, Australia
11 Sunshine Coast University Hospital, Kawana Waters, Queensland, Australia
12 Fiona Stanley Hospital, Murdoch, Western Australia, Australia, School of Public Health & Preventive Medicine, Monash University, Melbourne, Victoria, Australia
13 Australasian Leukaemia and Lymphoma Group, Melbourne, Victoria, Australia
14 Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia, WriteSource Medical Pty Ltd, North Sydney, New South Wales, Australia
15 Dept of Molecular Imaging and Therapeutics, Austin Health, Melbourne, Victoria, Australia
16 Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Victoria, Australia, School of Public Health & Preventive Medicine, Monash University, Melbourne, Victoria, Australia
17 Dep of Haematology, Monash Health, Melbourne, Victoria, Australia, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
18 Fiona Stanley Hospital, Murdoch, Western Australia, Australia, PathWest Laboratory Medicine, Perth, Western Australia, Australia, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
ABSTRACT
Background:
Primary central nervous system lymphoma (PCNSL) is an aggressive disease of predominantly older patients (pts). Current standard of care is intensive chemoimmunotherapy (CIT) such as MATRix (high-dose methotrexate [HD-MTX], cytarabine [Ara-C], thiotepa, rituximab) [PMID: 35562406] or R-MPV/Ara-C (rituximab, HD-MTX, procarbazine, vincristine followed by Ara-C) [PMID: 24101038], with consolidative autologous stem cell transplantation (ASCT) or whole brain radiotherapy (WBRT) for suitable pts.
Consolidative therapy is not suitable for many pts due to considerable toxicity, and questions remain regarding the benefit particularly following complete response (CR) to induction CIT. Sparing pts from WBRT-related cognitive impairment and morbidity and mortality of ASCT as well as developing novel approaches for pts not eligible for either consolidative strategy are key priorities.
PCNSL genomic interrogation has demonstrated copy number alterations and translocations affecting chromosome 9p24.1 (encoding loci for PD-L1 and PD-L2), providing therapeutic rationale for treatment with PD-1 inhibition [WHO-HAEM5]. Data in relapsed PCNSL have demonstrated efficacy of PD-1 inhibition [PMID: 28356247]. Here we report initial primary endpoint findings from the phase II, single arm ALLG NHL32 (BLOCK PCNSL) trial of CIT followed by pembrolizumab (PD-1 inhibitor) maintenance.
Methods:
NHL32 (ACTRN12619000518167) was designed using Fleming-A’Hern early phase principles [PMID: 11252008]. Adult pts with PCNSL were eligible if they had treatment-naïve histologically confirmed CNS diffuse large B-cell lymphoma, ECOG performance status 0-2 (post-steroid administration, if required), and adequate organ function. Key exclusion included active autoimmune disease and previous treatment with PD-1 inhibition.
Eligible pts received investigator-choice of R-MPV/Ara-C or MATRix CIT. Pts who achieved stable disease or better and adequate resolution of toxicity (i.e. grade <3 adverse event [AE]) after induction CIT proceeded to maintenance pembrolizumab (200mg) administered intravenously every 21 days for 35 cycles or until disease progression (PD).
The primary endpoint is progression-free survival (PFS) at 1-year from commencement of CIT. Secondary endpoints include 2-year and overall PFS, overall survival (OS), overall response rate (ORR) and safety. Exploratory radiological and translational research endpoints include PET utility for treatment response, tumour molecular profiling, gene expression profiling for immune gene signatures and cell of origin, PD-1/PD-L1 immunohistochemistry, 9p24 FISH and circulating tumour DNA (plasma and CSF). Planned interim analysis was performed to assess for safety and efficacy 1-year after 40 evaluable pts commenced CIT.
Results:
45 pts were enrolled between 2022-2025. Patient characteristics include median age 67 years (27-82), 53% male with ECOG 2 PS in 24% pts. 28/45 (62%) received R-MPV/Ara-C. The R-MPV cohort was older (71.9y vs 54.6y, p<0.001) with lower baseline cognition (mean MMSE 23.3 [5-30] vs 27.2 [20-30], p=0.045). In the entire cohort following CIT, investigator-assessed ORR was 64% (CR/CRu: 47%). At interim analysis, 33/45 (73%) pts received pembrolizumab maintenance. The commonest reason for not proceeding to pembrolizumab was PD (6/45; 13%) followed by pt withdrawal/investigator decision (4/45; [9%]). 6/33 (18%) pts discontinued pembrolizumab due to PD. Pembrolizumab treatment-related AEs (rAEs) affected 19/33 pts (58%) (grade 3: 9/33 [27%]), resulting in therapy cessation in 4/33 pts (12%).
At a median follow-up of 17 months (11.3-20.7), 1-year PFS and OS were 65% (95% CI: 47.9-77.6%) and 84% (67.7-92.5%) respectively. R-MPV and MATRix outcomes were similar: 1-year PFS of 63.1% (40.9%-78.9%) vs 68.2% (39.5%-85.4%), 1-year OS 81.9% (58.6%,92.8%) vs 84.0% (67.7%,92.5%).
There were 9 (20%) deaths, 4/9 (44%) prior to receiving pembrolizumab and 5/9 (56%) during/post pembrolizumab administration, respectively. 7/9 (78%) deaths were due to PD; 1/9 (11%) due to a cardiovascular event in the pre-pembrolizumab phase, and 1/9 (11%) due to infection during follow-up in a pt with PD beyond the AE reporting period.
Conclusion:
Pembrolizumab maintenance following induction CIT for pts with PCNSL was well-tolerated and with early follow-up yielding comparable survival outcomes to contemporary consolidative treatment strategies. Biomarker studies are underway to assess for predictive markers of response.